ALPHARMA INC
10-Q/A, EX-27, 2000-11-15
PHARMACEUTICAL PREPARATIONS
Previous: ALPHARMA INC, 10-Q/A, 2000-11-15
Next: ALPHARMA INC, 10-Q/A, 2000-11-15



<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                          12,841
<SECURITIES>                                         0
<RECEIVABLES>                                  169,587
<ALLOWANCES>                                         0
<INVENTORY>                                    177,740
<CURRENT-ASSETS>                               373,809
<PP&E>                                         414,671
<DEPRECIATION>                                 175,557
<TOTAL-ASSETS>                               1,132,000
<CURRENT-LIABILITIES>                          153,478
<BONDS>                                        368,396
                                0
                                          0
<COMMON>                                         6,001
<OTHER-SE>                                     339,579
<TOTAL-LIABILITY-AND-EQUITY>                 1,132,000
<SALES>                                        186,078
<TOTAL-REVENUES>                               186,078
<CGS>                                           97,042
<TOTAL-COSTS>                                   97,042
<OTHER-EXPENSES>                                63,097
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              10,860
<INCOME-PRETAX>                                 16,027
<INCOME-TAX>                                     5,662
<INCOME-CONTINUING>                             10,365
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    10,365
<EPS-BASIC>                                        .35
<EPS-DILUTED>                                      .33


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission